Ansell Limited (PD1A) - Net Assets

Latest as of June 2025: €1.98 Billion EUR ≈ $2.32 Billion USD

Based on the latest financial reports, Ansell Limited (PD1A) has net assets worth €1.98 Billion EUR (≈ $2.32 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.32 Billion ≈ $3.88 Billion USD) and total liabilities (€1.34 Billion ≈ $1.57 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Ansell Limited tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets €1.98 Billion
% of Total Assets 59.68%
Annual Growth Rate 5.8%
5-Year Change 26.72%
10-Year Change 29.53%
Growth Volatility 27.89

Ansell Limited - Net Assets Trend (2004–2025)

This chart illustrates how Ansell Limited's net assets have evolved over time, based on quarterly financial data. See Ansell Limited defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Ansell Limited (2004–2025)

The table below shows the annual net assets of Ansell Limited from 2004 to 2025. For live valuation and market cap data, see Ansell Limited market cap and net worth.

Year Net Assets Change
2025-06-30 €1.98 Billion
≈ $2.32 Billion
+3.80%
2024-06-30 €1.91 Billion
≈ $2.23 Billion
+18.25%
2023-06-30 €1.62 Billion
≈ $1.89 Billion
+3.78%
2022-06-30 €1.56 Billion
≈ $1.82 Billion
-0.51%
2021-06-30 €1.56 Billion
≈ $1.83 Billion
-23.49%
2020-06-30 €2.04 Billion
≈ $2.39 Billion
+1.68%
2019-06-30 €2.01 Billion
≈ $2.35 Billion
-4.11%
2018-06-30 €2.10 Billion
≈ $2.45 Billion
+31.30%
2017-06-30 €1.60 Billion
≈ $1.87 Billion
+4.36%
2016-06-30 €1.53 Billion
≈ $1.79 Billion
+31.21%
2015-06-30 €1.17 Billion
≈ $1.36 Billion
+2.29%
2014-06-30 €1.14 Billion
≈ $1.33 Billion
+90.97%
2006-06-30 €597.22 Million
≈ $698.22 Million
+32.01%
2005-06-30 €452.40 Million
≈ $528.90 Million
-25.50%
2004-06-30 €607.26 Million
≈ $709.95 Million
--

Equity Component Analysis

This analysis shows how different components contribute to Ansell Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 128744668000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (June 2025)

Component Amount Percentage
Retained Earnings €1.10 Billion 55.88%
Other Components €866.40 Million 44.12%
Total Equity €1.96 Billion 100.00%

Ansell Limited Competitors by Market Cap

The table below lists competitors of Ansell Limited ranked by their market capitalization.

Company Market Cap
Shandong Humon Smelting Co Ltd
SHE:002237
$2.63 Billion
Tarsus Pharmaceuticals Inc
NASDAQ:TARS
$2.63 Billion
Atlanta Braves Holdings, Inc. Series C Common Stock
NASDAQ:BATRK
$2.63 Billion
Almirall S.A.
MC:ALM
$2.63 Billion
CES Energy Solutions Corp
TO:CEU
$2.63 Billion
CLARIANT ADR 1/SF 4
F:CLRS
$2.63 Billion
Momentum Metropolitan Holdings Ltd
JSE:MTM
$2.63 Billion
TP ICAP GROUP PLC LS -25
F:8D7
$2.63 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Ansell Limited's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 1,894,900,000 to 1,963,600,000, a change of 68,700,000 (3.6%).
  • Net income of 101,600,000 contributed positively to equity growth.
  • Dividend payments of 63,700,000 reduced retained earnings.
  • Share repurchases of 4,400,000 reduced equity.
  • Other factors increased equity by 35,200,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income €101.60 Million +5.17%
Dividends Paid €63.70 Million -3.24%
Share Repurchases €4.40 Million -0.22%
Other Changes €35.20 Million +1.79%
Total Change €- 3.63%

Book Value vs Market Value Analysis

This analysis compares Ansell Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.15x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 1.46x to 1.15x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2017-06-30 €10.69 €15.60 x
2018-06-30 €14.59 €15.60 x
2019-06-30 €15.07 €15.60 x
2020-06-30 €15.78 €15.60 x
2021-06-30 €12.18 €15.60 x
2022-06-30 €12.26 €15.60 x
2023-06-30 €12.70 €15.60 x
2024-06-30 €13.04 €15.60 x
2025-06-30 €13.52 €15.60 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Ansell Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 5.17%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 5.07%
  • • Asset Turnover: 0.60x
  • • Equity Multiplier: 1.69x
  • Recent ROE (5.17%) is below the historical average (12.58%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2004 10.28% 7.99% 0.72x 1.79x €1.68 Million
2005 21.91% 11.72% 0.93x 2.02x €53.90 Million
2006 14.46% 10.27% 0.77x 1.83x €26.65 Million
2014 3.72% 2.63% 0.67x 2.10x €-70.70 Million
2015 16.28% 11.40% 0.69x 2.06x €72.32 Million
2016 14.19% 10.12% 0.69x 2.04x €63.29 Million
2017 12.20% 10.75% 0.56x 2.02x €34.59 Million
2018 31.56% 32.51% 0.59x 1.64x €447.63 Million
2019 7.99% 7.45% 0.63x 1.70x €-40.13 Million
2020 11.40% 9.83% 0.66x 1.76x €28.49 Million
2021 15.90% 12.17% 0.74x 1.76x €91.58 Million
2022 10.29% 8.13% 0.78x 1.62x €4.41 Million
2023 9.26% 8.96% 0.65x 1.58x €-11.79 Million
2024 4.04% 4.72% 0.50x 1.71x €-112.99 Million
2025 5.17% 5.07% 0.60x 1.69x €-94.76 Million

Industry Comparison

This section compares Ansell Limited's net assets metrics with peer companies in the Medical Instruments & Supplies industry.

Industry Context

  • Industry: Medical Instruments & Supplies
  • Average net assets among peers: $6,655,403,596
  • Average return on equity (ROE) among peers: -5.30%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Ansell Limited (PD1A) €1.98 Billion 10.28% 0.68x $2.63 Billion
SCHOTT Pharma AG & Co. KGaA (1SXP) $709.04 Million 17.68% 0.69x $2.39 Billion
RENAU.UNSP.ARD 1/5 EO-20 (56S0) $2.67 Billion 11.61% 1.89x $15.47 Billion
MEDIMI AB AK (79T) $15.24 Million -107.34% 0.16x $365.27K
TEVANO SYSTEMS HLDGS INC. (7RBA) $-736.70K 0.00% 0.00x $210.67K
STEVANATO GROUP SPA O.N. (87N) $1.40 Billion 8.39% 0.66x $906.61 Million
Carl Zeiss Meditec AG (AFX) $1.42 Billion 11.27% 0.43x $2.23 Billion
CARL ZEISS MEDITEC ADR 1 (AFXA) $2.03 Billion 14.48% 0.39x $2.14 Billion
Bio-gate AG (BIG1) $4.25 Million -42.46% 0.46x $7.12 Million
COLOPLAST SP.ADR 1/10 DK1 (CBH) $17.30 Billion 27.65% 1.78x $12.73 Billion
ESSILORLUXOTTICA 1/2/O.N. (ESLC) $41.00 Billion 5.75% 0.57x $78.07 Billion

About Ansell Limited

F:PD1A Germany Medical Instruments & Supplies
Market Cap
$2.63 Billion
€2.25 Billion EUR
Market Cap Rank
#5352 Global
#851 in Germany
Share Price
€15.60
Change (1 day)
-0.64%
52-Week Range
€15.50 - €21.00
All Time High
€23.56
About

Ansell Limited designs, sources, develops, manufactures, distributes, and sells hand and body protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates through two segments: Healthcare and Industrial. The Healthcare segment manufactures and markets solutions, including surgical gloves, single-use and examination gloves,… Read more